Campbell & Co Investment Adviser’s NovoCure NVCR Stock Holding History

Campbell & Co Investment Adviser’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-49,367	Closed	-$638K	–	1311
2025 Q4	$638K	Buy	49,367 +19,614	+66%	+$252K	0.03%	736
2025 Q3	$384K	Sell	29,753 -10,438	-26%	-$139K	0.03%	820
2025 Q2	$715K	Buy	+40,191	New	+$700K	0.05%	649
2024 Q3	–	Sell	-15,776	Closed	-$270K	–	1252
2024 Q2	$270K	Buy	+15,776	New	+$277K	0.02%	865
2023 Q4	–	Sell	-46,416	Closed	-$750K	–	1272
2023 Q3	$750K	Buy	+46,416	New	+$1.34M	0.09%	369
2022 Q3	–	Sell	-3,066	Closed	-$213K	–	857
2022 Q2	$213K	Buy	+3,066	New	+$231K	0.06%	585
2022 Q1	–	Sell	-7,200	Closed	-$541K	–	835
2021 Q4	$541K	Buy	+7,200	New	+$723K	0.19%	175
2021 Q3	–	Sell	-1,300	Closed	-$288K	–	705
2021 Q2	$288K	Buy	+1,300	New	+$253K	0.12%	336
2020 Q1	–	Sell	-2,848	Closed	-$240K	–	356
2019 Q4	$240K	Buy	+2,848	New	+$230K	0.07%	509
2019 Q3	–	Sell	-3,805	Closed	-$241K	–	710
2019 Q2	$241K	Buy	+3,805	New	+$193K	0.11%	398
2018 Q3	–	Sell	-7,700	Closed	-$241K	–	482
2018 Q2	$241K	Buy	+7,700	New	+$214K	0.19%	261

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Campbell & Co Investment Adviser's NVCR Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 49,367 shares — an estimated $638K sold.

Campbell & Co Investment Adviser first reported a position in NVCR in Q2 2018 and held it in 11 quarters. The position peaked at $750K in Q3 2023. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Campbell & Co Investment Adviser reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
Campbell & Co Investment Adviser sold 49,367 NovoCure shares in Q1 2026, an estimated $638K.
Campbell & Co Investment Adviser first reported a position in NovoCure in Q2 2018 and held it in 11 quarters.
Campbell & Co Investment Adviser's NovoCure position peaked at $750K in Q3 2023.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.